New Drugs for an Old Foe: Mycobacterium tuberculosis Meets PSC-Derived Macrophages

Kathrin Haake; Nico Lachmann

doi:10.1016/j.stemcr.2019.11.006

New Drugs for an Old Foe: Mycobacterium tuberculosis Meets PSC-Derived Macrophages

Stem Cell Reports. 2019 Dec 10;13(6):957-959. doi: 10.1016/j.stemcr.2019.11.006.

Authors

Kathrin Haake¹, Nico Lachmann²

Affiliations

¹ Institute of Experimental Hematology, RG Translational Hematology of Congenital Diseases, Hannover Medical School, Hannover, Germany; REBIRTH - Research Center for Translational and Regenerative Medicine, Hannover Medical School, Hannover, Germany.
² Institute of Experimental Hematology, RG Translational Hematology of Congenital Diseases, Hannover Medical School, Hannover, Germany; REBIRTH - Research Center for Translational and Regenerative Medicine, Hannover Medical School, Hannover, Germany. Electronic address: lachmann.nico@mh-hannover.de.

Abstract

Infections with Mycobacterium tuberculosis (Mtb) are still among the top 10 causes of death worldwide, highlighting the utmost need for new forms of medical treatments. In this issue of Stem Cell Reports, Han et al. (2019) describe a technique to screen therapeutically active compounds targeting Mtb using pluripotent stem cell-derived macrophages.

MeSH terms

Antitubercular Agents / pharmacology*
Cell Differentiation
Drug Discovery* / methods
Humans
Induced Pluripotent Stem Cells
Macrophages / cytology*
Macrophages / drug effects
Macrophages / metabolism
Macrophages / microbiology*
Mycobacterium tuberculosis / drug effects*
Mycobacterium tuberculosis / physiology
Pluripotent Stem Cells / cytology*
Pluripotent Stem Cells / metabolism

Substances

Antitubercular Agents